Advanced Clinician Scientist
PD Dr. med. Eva Rettinger
Department of Pediatric and Adolescent Medicine
Research Project: HER2/ErbB2-chimeric antigen receptor (CAR)-modified lymphocyte-centered immunotherapies for the clinical use in relapsed/refractory (r/r) childhood soft tissue sarcoma (STS)
Contact: rettinger@med.uni-frankfurt.de
Rettinger Lab
The aim of the Rettinger Lab is to generate and conduct comparative preclinical testing of tumor-specific, CAR-modified cytokine-induced killer cells (CIK cells) with conventional CAR-T cells as a novel targeted cancer immunotherapy, with the intention of translating this into clinical trials for the treatment of patients with high-risk tumors or leukemias in the near future. Since CAR-CIK cells must be safe for use in humans and at the same time inexpensive to produce, a Sleeping Beauty transposon-based method is preferable to the conventional viral gene modification method for the genetic modification of CIK cells. In this method, the blueprint for the Sleeping Beauty protein and the blueprint for the CAR are introduced into the cells with an electric impulse.
Find out more about the Rettinger Lab here.
